Benchmark indices ended lower on January 20 on the back of continues profit booking, with Nifty closing below 17800.
At close, the Sensex was down 634.20 points or 1.06% at 59,464.62, and the Nifty was down 181.40 points or 1.01% at 17,757. About 1593 shares have advanced, 1606 shares declined, and 64 shares are unchanged.
Bajaj Finserv, Infosys, TCS, Divis Lab and Bajaj Auto were the top Nifty losers, while gainers included Power Grid Corporation, Bharti Airtel, Grasim Industries, JSW Steel and Britannia Industries.
Except power, realty and metal, all other sectoral indices are trading in the red with auto, IT, FMCG and pharma indices down 0.8-1.7 percent. BSE midcap and smallcap indices ended flat.
JM Financial Private Equity has finalized a total investment round of Rs 1,000 mn, along with co-investors, as a part of Series B fund raise in a Bengaluru based agri-digital platform, BigHaat Agro Pvt Ltd, to fund the Company’s current growth plans.
Beyond Next Ventures, one of the earlier investors in BigHaat also participated in the fund raise. Proceeds from the investment will support augmentation of the existing technology infrastructure and accelerate expansion of the company’s operations.
This marks the closing of the ninth investment by JM Financial India Fund II. Set up in 2015, BigHaat functions on a unique direct-to-farmer model and is transforming the agriculture value chain by leveraging science, data and technology.
JM Financial was quoting at Rs 74.70, up Rs 0.05, or 0.07 percent on the BSE.
SMS Pharmaceuticals has received a non-exclusive license through the Medicines Patent Pool (MPP) to manufacture molnupiravir, an investigational antiviral Covid-19 medicine, to increase broad access of treatment in 105 low-and middle income countries (UMIC).
SMS Pharmaceuticals was quoting at Rs 136.50, up Rs 5.40, or 4.12 percent on the BSE.
Strides Pharma Science announced its partnership with Medicines Patent Pool (MPP) to commercialize molnupiravir in the international markets, as per the company release.
Strides Pharma Science was quoting at Rs 421.55, down Rs 0.30, or 0.07 percent on the BSE.
Bajaj Finserv has posted 2.6 percent fall in its Q3 net profit at Rs 1,256 crore against Rs 1,289 crore and revenue was up 10.2% at Rs 17,587 crore versus Rs 15,958 crore, YoY.
Bajaj Finserv was quoting at Rs 17,248.40, down Rs 839.15, or 4.64 percent on the BSE.